+

MX2009007001A - Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. - Google Patents

Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.

Info

Publication number
MX2009007001A
MX2009007001A MX2009007001A MX2009007001A MX2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A MX 2009007001 A MX2009007001 A MX 2009007001A
Authority
MX
Mexico
Prior art keywords
polypeptides
amino acids
phenazine
natural amino
substituted amino
Prior art date
Application number
MX2009007001A
Other languages
English (en)
Inventor
Zhenwei Miao
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of MX2009007001A publication Critical patent/MX2009007001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C07K14/615—Extraction from natural sources

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se revelan en la presente aminoácidos no naturales y polipéptidos que incluyen por lo menos un aminoácido no natural y métodos para la fabricación de tales aminoácidos no naturales y polipéptidos. Los aminoácidos no naturales, por si mismos o como parte de un polipéptido, pueden incluir un sustituyente de fenazina o quinoxalina. También se revelan en la presente polipéptidos de aminoácidos no naturales que son modificados además post-traduccionalmente, métodos para efectuar tales modificaciones y métodos para la purificación de tales polipéptidos.
MX2009007001A 2006-12-28 2007-12-28 Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. MX2009007001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88250006P 2006-12-28 2006-12-28
PCT/US2007/089142 WO2008083346A1 (en) 2006-12-28 2007-12-28 Phenazine and quinoxaline substituted amino acids and polypeptides

Publications (1)

Publication Number Publication Date
MX2009007001A true MX2009007001A (es) 2009-07-10

Family

ID=39589004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007001A MX2009007001A (es) 2006-12-28 2007-12-28 Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.

Country Status (8)

Country Link
US (1) US20100098630A1 (es)
EP (1) EP2076500A4 (es)
JP (1) JP2010514808A (es)
KR (1) KR20090102838A (es)
AU (1) AU2007341997A1 (es)
CA (1) CA2671851A1 (es)
MX (1) MX2009007001A (es)
WO (1) WO2008083346A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2068909T3 (da) 2007-03-30 2012-08-06 Ambrx Inc Modificerede FGF-21-polypeptider og anvendelse heraf
EP2350112A4 (en) * 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG10201913122WA (en) 2010-08-17 2020-03-30 Ambrx Inc Modified relaxin polypeptides and their uses
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
WO2013130814A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Novel prodrug containing molecule compostions and their uses
EP3459942B1 (en) 2012-04-24 2020-12-30 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CN104583235B (zh) 2012-06-08 2019-03-01 苏特罗生物制药公司 含位点特异非天然氨基酸残基的抗体、其制备和使用方法
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
HUE045227T2 (hu) 2012-08-31 2019-12-30 Sutro Biopharma Inc Azido csoportot tartalmazó módosított aminosavak
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
PT2968552T (pt) 2013-03-14 2020-05-18 Scripps Research Inst Anticorpo dos agentes alvo, combinações e uso para os mesmos
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
AU2015335603B2 (en) 2014-10-24 2020-04-30 Bristol-Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP3411069B1 (en) 2016-02-04 2024-07-10 The Scripps Research Institute Humanized anti-cd3 antibodies, conjugates and uses thereof
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
RS65268B1 (sr) 2018-09-11 2024-03-29 Ambrx Inc Polipeptidni konjugati interleukina-2 i njihova upotreba
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN113368111B (zh) * 2020-03-10 2022-04-22 四川大学 一种吩嗪羧酸类化合物的抗肿瘤作用
CN111440087A (zh) * 2020-04-08 2020-07-24 南京优氟医药科技有限公司 氧-[2-[2-[2-(2-甲氧基乙氧基)乙氧基]乙氧基]乙基]羟胺的生产工艺
CN113008853B (zh) * 2021-02-25 2023-01-24 中国工程物理研究院化工材料研究所 基于荧光含能分子对炸药的原位标记与视觉示踪的方法
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
WO2024155627A1 (en) 2023-01-16 2024-07-25 Ambrx, Inc. Anti-cd70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4170654A (en) * 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US5118675A (en) * 1991-02-15 1992-06-02 American Home Products Corporation Quinoxaline phosphono-amino acids
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen

Also Published As

Publication number Publication date
EP2076500A4 (en) 2009-12-09
KR20090102838A (ko) 2009-09-30
AU2007341997A1 (en) 2008-07-10
WO2008083346A1 (en) 2008-07-10
JP2010514808A (ja) 2010-05-06
US20100098630A1 (en) 2010-04-22
CA2671851A1 (en) 2008-07-10
EP2076500A1 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
MX2009007001A (es) Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos.
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007059312A3 (en) Methods and compositions comprising non-natural amino acids
GB2438982A (en) Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
IN2012DN01652A (es)
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
NZ600690A (en) Fkbp-l and uses thereof
NZ596658A (en) Dig-10 insecticidal cry toxins
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
MX354993B (es) Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
IN2012DN05169A (es)
WO2006127757A3 (en) Interferon-igg fusion
IN2012DN02981A (es)
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
PL1664108T3 (pl) Rozdzielanie polipeptydów zawierających racemizowany aminokwas
WO2011063320A3 (en) Recombinant filaggrin polypeptides for cell importation
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
WO2006132739A3 (en) Novel chemical compounds
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
IL192212A0 (en) Composition containing several botulic toxins
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2006127458A3 (en) Novel chemical compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载